Clinical Trial Update: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing post-transplant high-dose cyclosporine as GvHD prophylaxis in 1 HLA-mismatched unrelated hematopoietic stem cell transpl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Malignancies

Drugs mentioned

• CYCLOSPORINE (cyclosporine)

Snippet

Sponsor: Gruppo Italiano Trapianto di Midollo Osseo | Conditions: Myeloid Malignancies | Phase 2 | Status: COMPLETED